共 50 条
- [41] Real-World Safety and Efficacy of Ribavirin-free regimen of Ombitasvir/Paritaprevir/Ritonavir for dialysis patients infected with HCVHEPATOLOGY, 2017, 66 : 576A - 576ADerbala, MoutazChandra, PremMohiuddin, Syed A.Amer, AliaaElsayad, ElhamAl-Ali, Fadwa S.Khater, Iman I.
- [42] Paritaprevir/Ritonavir/Ombitasvir plus Dasabuvir regimen in the treatment of genotype 1 chronic hepatitis C infection in kidney transplant candidates.JOURNAL OF VIRAL HEPATITIS, 2018, 25 : 71 - 72Sperl, J.Kreidlova, M.Senkerikova, R.Chmelova, K.Merta, D.Frankova, S.
- [43] Effectiveness of 8-and 12-Week Treatment with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naive HCV Patients in a Real-Life Setting in Romania: the AMETHYST StudyJOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2021, 30 (01) : 88 - 93Trifan, AncaStanciu, CarolIliescu, LauraSporea, IoanBaroiu, LilianaDiculescu, MirceaLuca, Mihaela-CatalinaMiftode, EgidiaCijevschi, CristinaMihai, CatalinaSparchez, Zeno-AdrianPojoga, CristinaStreinu-Cercel, AdrianGheorghe, Liliana
- [44] Effectiveness of dasabuvir, ombitasvir/paritaprevir/ritonavir (DSV plus OBV/PTV/r) for HCV genotype 1 in HIV/HCV co-infected subjects with compensated liver disease: real-world experience from the MADRID-CoRe studyJOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19Gonzalez-Garcia, JuanLuisa Montes-Ramirez, MariaDominguez-Dominguez, LourdesAldamiz-Echevarria, TeresaJesus Vivancos, M.Gil-Martin, AngelaCruz-Martos, EncarnacionEstrada, VicenteArias, AnaSanz, JoseGaspar, GabrielLosa, JuanBarros, CarlosRuiz-Giardin, JoseGimeno-Garcia, AlejandraVegas, AnaTeresa Garcia-Benayas, M.Serrano, ReginoJose Calvo, M.Alcaraz, MartaJarrin, InmaculadaBerenguer, Juan
- [45] Effectiveness And Safety Of Ombitasvir, Paritaprevir/Ritonavir And Sofosfuvir/Ledipasvir In Patients With Genotype 4 Chronic Hepatitis C Virus Infection: Results From The Spanish Real World CohortHEPATOLOGY, 2016, 64 : 486A - 487ACrespo, JavierCalleja, Jose L.Begona, SacristranRuiz-Antoran, BelenAmpuero, JavierGarcia-Samaniego, JavierGea, FranciscoButi, MariaLens, SabelaCabezas, JoaquinMorillas, Rosa MaraSalcines, Jose RamonPascasio, Juan ManuelTurnes, JuanSaez-Royuela, FedericoArenas, JuanRincon, DiegoPrieto, MartinJorquera, FranciscoRuano, Juan Jose SanchezNavascues, CarmenMolina, EstherTorras, XavierMontoliu, SilviaMoreno, Jose M.Serra, Miguel AngelAndrade, Raul J.Fernandez-Rodriuez, Conrado M.Fernandez-Bermejo, MiguelSimon, Miguel A.Bonet, Luciade la Vega, JuanDiago, MoisesFernandez, Jose RamonSanchez-Antolin, GloriaFernandez, Inmaculada
- [46] The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort studyBMC Infectious Diseases, 18Ewa JanczewskaDorota Zarębska-MichalukHanna BerakAnna PiekarskaAndrzej GietkaDorota DybowskaWłodzimierz MazurTeresa Belica-WdowikWitold DobrackiMagdalena Tudrujek-ZdunekZbigniew DerońIwona BuczyńskaMarek SitkoAgnieszka Czauż-AndrzejukBeata LorencJolanta Białkowska-WarzechaJolanta CitkoŁukasz LauransJerzy JaroszewiczŁukasz SochaOlga TroninaBrygida AdamekAndrzej HorbanWaldemar HalotaBarbara Baka-ĆwierzKrzysztof TomasiewiczKrzysztof SimonAleksander GarlickiMarta Wawrzynowicz-SyczewskaRobert Flisiak
- [47] The efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort studyBMC INFECTIOUS DISEASES, 2018, 18Janczewska, EwaZarebska-Michaluk, DorotaBerak, HannaPiekarska, AnnaGietka, AndrzejDybowska, DorotaMazur, WlodzimierzBelica-Wdowik, TeresaDobracki, WitoldTudrujek-Zdunek, MagdalenaDeron, ZbigniewBuczynska, IwonaSitko, MarekCzauz-Andrzejuk, AgnieszkaLorenc, BeataBialkowska-Warzecha, JolantaCitko, JolantaLaurans, LukaszJaroszewicz, JerzySocha, LukaszTronina, OlgaAdamek, BrygidaHorban, AndrzejHalota, WaldemarBaka-Cwierz, BarbaraTomasiewicz, KrzysztofSimon, KrzysztofGarlicki, AleksanderWawrzynowicz-Syczewska, MartaFlisiak, Robert
- [48] Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in TaiwanJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 (03) : 710 - 717Liu, Chen-HuaLiu, Chun-JenSu, Tung-HungYang, Hung-ChihHong, Chun-MingTseng, Tai-ChungChen, Pei-JerChen, Ding-ShinnKao, Jia-Horng
- [49] Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experienceJOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2018, 117 (06) : 518 - 526Yu, Ming-LungChen, Yao-LiHuang, Chung-FengLin, Kuo-HuaYeh, Ming-LunHuang, Ching-IHsieh, Meng-HsuanLin, Zu-YauChen, Shinn-CherngHuang, Jee-FuDai, Chia-YenChuang, Wan-Long
- [50] Real-world efficacy and safety of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with HCV genotype 1 and 4 infection, final results of the AMBER studyHEPATOLOGY, 2016, 64 : 987A - 987AFlisiak, RobertJanczewska, EwaWawrzynowicz-Syczewska, MartaJaroszewicz, JerzyZarebska-Michaluk, DorotaNazzal, KhalilBolewska, Beata G.Bialkowska, JolantaBerak, HannaFleischer-Stepniewska, Katarzyna M.Tomasiewicz, KrzysztofKarwowska, KorneliaRostkowska, KarolinaPiekarska, AnnaTronina, OlgaMadej, GrzegorzGarlicki, AleksanderLucejko, MariuszPisula, ArkadiuszKarpinska, Ewa A.Kryczka, WieslawWiercinska-Drapalo, AliciaMozer-Lisewska, IwonaJablkowski, Maciej S.Horban, AndrzejKnysz, BrygidaTudrujek, MagdalenaHalota, WaldemarSimon, Krzysztof.